Answer
Taking emtricitabine/tenofovir disoproxil with didanosine increases didanosine exposure by 40–60%, potentially increasing toxicity (including rare, sometimes fatal pancreatitis and lactic acidosis), while coadministration with didanosine 400 mg/day has been associated with significant CD4-count reductions and 250 mg/day with high virological failure rates in several tested HIV-1 treatment combinations.
Sources for this answer
- Emtricitabine/Tenofovir disoproxil Dr. Reddy's 200 mg/245 mg Film-Coated TabletsDr. Reddy's Laboratories (UK) Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 11Document updated
Sources checked